Ivonescimab Shows Survival Advantage Over Keytruda in Lung Cancer Trial on September 14, 2026 Akeso Antibodies, Bispecific Ivonescimab Keytruda Non-Small Cell Lung Carcinoma non-small-cell lung cancer Overall Survival PD-L1-high pembrolizumab Progression-Free Survival +
FDA expands Bayer’s Hyrnuo into first-line HER2-mutant lung cancer on September 10, 2026 Accelerated Approved Bayer Boehringer Ingelheim erbB-2 Receptor first-line therapy Hyrnuo Non-Small Cell Lung Carcinoma non-small-cell lung cancer sevabertinib United States Food and Drug Administration +
Ivonescimab’s Keytruda win raises the stakes for regulatory review and global adoption on September 03, 2026 Akeso EGFR-mutated Ivonescimab Keytruda Non-Small Cell Lung Carcinoma non-small-cell lung cancer Overall Survival pembrolizumab Progression-Free Survival United States Food and Drug Administration +
Akeso broadens ivonescimab ambitions after biliary tract cancer win on August 26, 2026 Akeso Biliary Tract Cancer durvalumab HARMONi-GI1 Imfinzi Ivonescimab Michelle Xia non-small-cell lung cancer Overall Survival Phase III +